11 · Client story
Crossfire
Building an IP-protected trojan horse against cancer
The Pivot Park business campus has a strong pharmaceutical heritage and is home to a range of leading and emerging companies in the Dutch biotech and pharma sector. One of these is Crossfire Oncology, which is developing a new class of anticancer therapies known as degrader–antibody conjugates (DACs). We spoke with Crossfire’s leadership team, along with their NLO patent attorney Kolja Adamczyk, about the development of the DAC platform and the role intellectual property plays in this process. "Strong intellectual property lies at the heart of developing novel medicines."
Crossfire Oncology is a biotech company based at Pivot Park, operating from a brand-new, state-of-the-art research facility named after the famous scientist Marie Curie. Pivot Park was established following the restructuring of research and development activities by MSD / Organon and has since developed into a thriving hub for biotech innovation. Crossfire was founded to leverage the strong kinase expertise built at MSD/Organon, which contributed to the development of acalabrutinib, a blockbuster kinase inhibitor marketed by AstraZeneca under the brand name Calquence. The Crossfire team brings decades of experience in medicinal chemistry and kinase biology and has contributed to the development of several clinically and commercially successful drugs. One example is BAL0891, a potent kinase inhibitor designed in-house and currently in clinical development for the treatment of advanced solid tumours and relapsed / refractory Acute Myeloid Leukaemia.
Kinase targeting therapeutics are well-established and widely used, with many companies working in this field. What sets Crossfire’s approach apart in this competitive landscape?
Rogier: "As our company name suggests, we approach kinases from multiple angles. In the past, we have developed small molecules that block the activity of kinases involved in cancer cell growth. We have also worked on degrader molecules that remove these kinases from cells altogether. Our current focus is on combining these approaches by linking degrader molecules (the payload) to antibodies, creating so-called degrader–antibody conjugates (DACs). These DACs act like a 'Trojan horse': they bind specifically to markers on cancer cells, which then internalise them.
Once inside the cell, the degrader is released and targets a kinase that the cancer cell needs to survive. This leads to the breakdown of that kinase, triggering programmed (cancer) cell death (apoptosis)."
Jos: "The concept of using antibodies as a Trojan horse is not new. Several companies have successfully developed antibodies with standard chemotherapy attached. This results in targeted delivery of chemotherapy, results in better efficacy and reduced toxicity. The challenge is that these companies all make use of the same limited number of payloads and essentially only focus on the horse (the antibody) and on how the payload is released once it is in the cancer cell. However, once a cancer cell has become resistant to the payload, the Trojan horse strategy is no longer effective because the cancer cell 'knows' what is coming.
At Crossfire, we focus on developing a completely novel payload to arm our Trojan horse. Our degrader specifically targets a kinase that drives tumour growth. In addition to providing a novel mechanism of action, this also introduces an additional layer of selectivity. This means we can target cancer cells more precisely while further limiting effects on healthy tissue.
We are now close to completing this platform, which will allow us to develop a range of products by combining our degrader molecules with different tumour-specific antibodies."
What is currently the most advanced project within Crossfire’s DAC platform?
Rogier: "Our most advanced project focuses on triple-negative breast cancer, an aggressive form that does not respond well to many of the targeted therapies used for other breast cancer types. As a result, treatment often relies on intensive chemotherapy, highlighting a clear unmet medical need. While several antibody–drug conjugates (ADCs) are currently being developed for this indication, many rely on payloads to which tumour cells can develop resistance. In contrast, our studies show that our degrader-based approach remains effective even in cells that have become resistant to these treatments.
We are currently in the preclinical stage, where we are evaluating the efficacy and safety of several candidate variants."
Crossfire operates in a highly competitive field. Given the critical importance of intellectual property in drug development, how do you establish and protect your position?
Erik: "You are absolutely right, strong intellectual property lies at the heart of developing novel medicines. To give you an idea, we are currently seeking new investors willing to commit several millions of euros to fund the remainder of our preclinical programme. Beyond that, extensive clinical testing and the production of commercial grade material will require hundreds of millions of euros in additional investment.
Investments on this scale are only possible if there is a clear path to a meaningful return. To achieve this, a strong and well-protected IP position is essential to making a product commercially viable. For this reason, we assess the IP potential of every new research direction at a very early stage, ensuring that our efforts are focused on approaches that offer a real opportunity to build and protect new intellectual property."
How is this implemented in your day-to-day operations?
Jos: "Everyone at Crossfire understands how critical intellectual property is to our success. We encourage our team to think freely and creatively, but once a new idea emerges, we challenge it: Is it truly novel? Is it inventive? Does it have clear commercial potential? And, importantly, what does the patent landscape look like? Do we have freedom to operate?
In addition, we continuously monitor developments in the field. Personally, I review the scientific literature on a daily basis to stay up to date with new insights and competing approaches."
What is NLO’s role in helping you manage and protect your IP?
Jos: "Just before this interview, Kolja and I spent an hour discussing a new idea we’re exploring. I can usually assess the novelty myself by reviewing the literature, but then I present it to Kolja, who challenges it from every angle. He pushes on key questions: Is this truly an invention? Do we have sufficient data to support our claims? Would additional data help us secure broader protection? And how likely is it that such claims will be granted? These kinds of in-depth discussions really help us refine our ideas and strengthen our overall IP strategy."
Rogier: "We spend significant time discussing timing: when is the right moment to file a patent application? Filing later gives us more time to develop, optimise and commercialise an invention, but it also increases the risk that others in the field may file similar applications first.
At the same time, as a biotech company, we need to engage with investors and potential partners early, something that requires a clearly secured IP position. Balancing these factors is a central part of our IP strategy."
Kolja: "As Crossfire’s patent attorney, I work with a highly experienced team that has a strong awareness of the importance of IP. This enables constructive, in-depth discussions on IP strategy and tactics, which I find particularly valuable. In many organisations, IP is primarily seen as an outcome of research and development. At Crossfire, however, it is an integrated part of the R&D process and actively helps to shape decision-making. Early engagement with investors and potential partners poses challenges to securing the strongest possible IP position in patent applications. Through our in-depth discussions on IP strategy and tactics, which extend beyond the next patent filing to the broader picture, we are able to balance these considerations. A strong IP position is something you build over time; it is constructed through a series of complementary patent applications that protect novel aspects of the technology, as well as further improvements as Crossfire progresses through preclinical and clinical development."
What defines a strong patent application?
Jos: "At the end of the day, a good IP position comes down to finding the right balance. You want to claim broadly, to create sufficient protection for the company and prevent competitors from bypassing our IP. But those claims need to be properly supported, otherwise they won’t hold up. Getting that balance right is what defines strong patents. It’s a subtle, sometimes challenging process, but also what makes it interesting."
Kolja: "Additionally, a strong understanding of the scientific background is essential. Equally important is understanding how to position an invention and its improvements within that context in a patent application. This influences how broadly you can claim and how convincingly those improvements can be presented. Presenting an invention in a patent is different from writing a scientific paper. It requires a good understanding of how patent applications are being assessed and, in practice, often means rephrasing or restructuring the same information to fit that context. Finally, ensuring the right level of supporting evidence for the claims is another important factor in a strong patent application."
Is Crossfire’s IP position viewed positively by potential partners and investors?
Rogier: "Based on our discussions with investors and potential partners, I would say yes. Before committing, they take a very close look at your company, particularly your IP position. So far, we’ve come through that process well."
Erik: "In our industry, company value is driven by three things: the quality of your products, the size of the markets you can address and the strength of your IP. With our DAC platform, we have the potential to target multiple cancer types. Combined with a solid IP position, it puts us in a strong place."
